Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.

Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.

Publication date: Dec 22, 2023

Cancer patients are at an increased risk of morbidity and mortality from SARS-CoV-2 infection and have a decreased immune response to vaccination. We conducted a study measuring both the neutralizing and total antibodies in cancer patients following a third dose of the mRNA-1273 COVID-19 vaccine. Immune responses were measured with an enzyme-linked immunosorbent assay (ELISA) and neutralization assays. Kruskal-Wallis tests were used to evaluate the association between patient characteristics and neutralization geometric mean titers (GMTs), and paired t-tests were used to compare the GMTs between different timepoints. Spearman correlation coefficients were calculated to determine the correlation between total antibody and neutralization GMTs. Among 238 adults diagnosed with cancer, a third dose of mRNA-1273 resulted in a 37-fold increase in neutralization GMT 28 days post-vaccination and maintained a 14. 6-fold increase at 6 months. Patients with solid tumors or lymphoid cancer had the highest and lowest neutralization GMTs, respectively, at both 28 days and 6 months post-dose 3. While total antibody GMTs in lymphoid patients continued to increase, other cancer types showed decreases in titers between 28 days and 6 months post-dose 3. A strong correlation (p < 0. 001) was found between total antibody and neutralization GMTs. The third dose of mRNA-1273 was able to elicit a robust neutralizing antibody response in cancer patients, which remained for 6 months after administration. Lymphoid cancer patients can benefit most from this third dose, as it was shown to continue to increase total antibody GMTs 6 months after vaccination.

Open Access PDF

Concepts Keywords
Cancer cancer patient
Elisa COVID-19
Spearman hematologic malignancy
Vaccination lymphoid cancer
neutralizing antibody


Type Source Name
disease VO dose
disease VO vaccine
disease MESH Cancer
disease MESH morbidity
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO immune response
disease VO vaccination
disease VO COVID-19 vaccine
disease IDO assay
disease VO USA
disease VO immunization
disease MESH Infection
disease MESH Infectious Diseases
disease IDO facility
disease MESH hematologic malignancy
disease VO population
disease VO vaccine dose
drug DRUGBANK Coenzyme M
drug DRUGBANK Medrysone
disease IDO process
disease IDO blood
disease IDO history
disease MESH seroconversion
disease VO titer
disease MESH avian influenza
drug DRUGBANK L-Tyrosine

Original Article

(Visited 1 times, 1 visits today)